Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?-Reference-Cited by-同舟云学术

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

Published:2019-01-03 Issue:5 Volume:46 Page:1081-1091
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

dos Santos José Carlos,Schäfer Martin,Bauder-Wüst Ulrike,Lehnert Wencke,Leotta Karin,Morgenstern Alfred,Kopka Klaus,Haberkorn Uwe,Mier Walter,Kratochwil Clemens^ORCID

Funder

Richard-Winter-Stiftung

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-018-4220-z.pdf

Reference38 articles.

1. Rubini G, Nicoletti A, Rubini D, Asabella AN. Radiometabolic treatment of bone-metastasizing cancer: from 186Rhenium to 223Radium. Cancer Biother Radiopharm. 2014;29:1–11. https://doi.org/10.1089/cbr.2013.1549 .

2. Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31. https://doi.org/10.2967/jnumed.117.191395 .

3. Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802. https://doi.org/10.2967/jnumed.117.203539 .

4. Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106–19. https://doi.org/10.1007/s00259-014-2857-9 .

5. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93–100. https://doi.org/10.1016/S0969-8051(99)00086-4 .

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [ ⁶⁸ Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer;Expert Review of Molecular Diagnostics;2024-07-02

2. Alpha and Beta Radiation for Theragnostics;PET Clinics;2024-07

3. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management;PET Clinics;2024-07

4. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective;Cancers;2024-04-25

5. Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent;Indian Journal of Nuclear Medicine;2024-03